Eachempati Soumitra R, Wang John C L, Hydo Lynn J, Shou Jian, Barie Philip S
Division of Critical Care and Trauma, Department of Surgery, Weill Medical College of Cornell University, New York, NY, USA.
J Trauma. 2007 Nov;63(5):987-93. doi: 10.1097/TA.0b013e3181574930.
Despite improved resuscitation and sepsis care, acute renal failure (ARF) remains common in critically ill surgical patients. New methods of renal replacement therapy (RRT) are being used in surgical intensive care units (SICUs), including high-flux hemodialysis (HD) and continuous RRT (CRRT). RRT is being used increasingly early in the course of ARF, but data are scant to suggest that mortality is improved. Consequently, we determined whether outcomes were improved with CRRT in SICU patients, and hypothesized that CRRT lowers mortality for patients with ARF.
Patients who developed ARF (acute increase in serum creatinine concentration >or=2.4 mg/dL) in the SICU from 1993 to 2004 were identified. Data collected prospectively included year of admission, age, gender, Acute Physiology and Chronic Health Evaluation (APACHE) III score, cumulative multiple organ dysfunction score and its individual components, cumulative nonrenal organ dysfunction score, and need for RRT. Patients were stratified January 1994 to January 2001 (pre-CRRT) and February 2001 to December 2004 (post-CRRT). The primary endpoint was mortality.
Among 8,505 SICU patients, 530 (6.2%) developed ARF. Three hundred and eleven patients were treated pre-CRRT and 219 thereafter. Female patients comprised 35% of ARF patients. The mean age was 69 years +/- 2 years, and the mean APACHE III score was 81 +/- 1 point for ARF patients. HD was performed in 15.6% of ARF patients before 2001 and 5.5% of ARF patients in 2001 and thereafter. CRRT was performed in 20.1% of ARF patients in 2001 and thereafter. Overall mortality for ARF patients was 45% (APACHE III normative predicted mortality: 55%) with no difference over time (pre-CRRT = 46.3%, post-CRRT = 45.2%, p = 0.86). Patients who required RRT had a mean APACHE III score of 91 +/- 1 point, with 61% mortality (predicted mortality: 67%), with no difference over time. Independent predictors of mortality overall and for ARF patients included age and the magnitude of renal, cardiovascular, hepatic, and neurologic dysfunction. In comparison with CRRT, HD was associated with a decreased risk of death.
Despite more frequent RRT and the use of CRRT, the mortality of ARF in critically ill surgical patients remains high because of nonrenal organ dysfunction. Considering that ARF-related mortality was decreased by intermittent HD, and that intermittent RRT is less costly, patients who need RRT should be treated preferentially with HD.
尽管复苏和脓毒症治疗有所改善,但急性肾衰竭(ARF)在重症外科患者中仍很常见。新的肾脏替代治疗(RRT)方法正在外科重症监护病房(SICU)中使用,包括高通量血液透析(HD)和连续性RRT(CRRT)。RRT在ARF病程中使用得越来越早,但几乎没有数据表明死亡率有所改善。因此,我们确定CRRT是否能改善SICU患者的预后,并假设CRRT可降低ARF患者的死亡率。
确定1993年至2004年在SICU发生ARF(血清肌酐浓度急性升高≥2.4mg/dL)的患者。前瞻性收集的数据包括入院年份、年龄、性别、急性生理与慢性健康状况评估(APACHE)III评分、累积多器官功能障碍评分及其各个组成部分、累积非肾脏器官功能障碍评分以及RRT需求。患者被分为1994年1月至2001年1月(CRRT前)和2001年2月至2004年12月(CRRT后)两组。主要终点是死亡率。
在8505例SICU患者中,530例(6.2%)发生ARF。311例患者在CRRT前接受治疗,此后有219例。女性患者占ARF患者的35%。ARF患者的平均年龄为69岁±2岁,平均APACHE III评分为81±1分。2001年前15.6%的ARF患者接受了HD治疗,2001年及以后这一比例为5.5%。2001年及以后20.1%的ARF患者接受了CRRT治疗。ARF患者的总体死亡率为45%(APACHE III标准预测死亡率:55%),随时间无差异(CRRT前=46.3%,CRRT后=45.2%,p=0.86)。需要RRT的患者平均APACHE III评分为91±1分,死亡率为61%(预测死亡率:67%),随时间无差异。总体及ARF患者死亡率的独立预测因素包括年龄以及肾脏、心血管、肝脏和神经功能障碍的严重程度。与CRRT相比,HD与死亡风险降低相关。
尽管RRT使用更频繁且采用了CRRT,但由于非肾脏器官功能障碍,重症外科患者中ARF的死亡率仍然很高。鉴于间歇性HD可降低ARF相关死亡率,且间歇性RRT成本更低,需要RRT的患者应优先接受HD治疗。